153 related articles for article (PubMed ID: 17961192)
1. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.
He YL; Sabo R; Campestrini J; Wang Y; Riviere GJ; Nielsen JC; Rosenberg M; Ligueros-Saylan M; Howard D; Dole WP
Br J Clin Pharmacol; 2008 Mar; 65(3):338-46. PubMed ID: 17961192
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL
Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
[TBL] [Abstract][Full Text] [Related]
3. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
He YL; Sabo R; Riviere GJ; Sunkara G; Leon S; Ligueros-Saylan M; Rosenberg M; Dole WP; Howard D
Curr Med Res Opin; 2007 May; 23(5):1131-8. PubMed ID: 17519080
[TBL] [Abstract][Full Text] [Related]
4. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.
He YL; Sabo R; Campestrini J; Wang Y; Ligueros-Saylan M; Lasseter KC; Dilzer SC; Howard D; Dole WP
Eur J Clin Pharmacol; 2007 Jul; 63(7):677-86. PubMed ID: 17486328
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.
Hu P; Yin Q; Deckert F; Jiang J; Liu D; Kjems L; Dole WP; He YL
J Clin Pharmacol; 2009 Jan; 49(1):39-49. PubMed ID: 18832295
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
He YL; Yamaguchi M; Ito H; Terao S; Sekiguchi K
Int J Clin Pharmacol Ther; 2010 Sep; 48(9):582-95. PubMed ID: 20860912
[TBL] [Abstract][Full Text] [Related]
7. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Sunkara G; Sabo R; Wang Y; He YL; Campestrini J; Rosenberg M; Howard D; Dole WP
J Clin Pharmacol; 2007 Sep; 47(9):1152-8. PubMed ID: 17656620
[TBL] [Abstract][Full Text] [Related]
8. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.
Landersdorfer CB; He YL; Jusko WJ
Br J Clin Pharmacol; 2012 Mar; 73(3):391-401. PubMed ID: 22442826
[TBL] [Abstract][Full Text] [Related]
10. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.
He YL; Flannery B; Campestrini J; Leon S; Zinny MA; Ligueros-Saylan M; Jarugula V
Curr Med Res Opin; 2008 Jun; 24(6):1703-9. PubMed ID: 18471347
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment.
He YL; Kulmatycki K; Zhang Y; Zhou W; Reynolds C; Ligueros-Saylan M; Taylor A
Int J Clin Pharmacol Ther; 2013 Sep; 51(9):693-703. PubMed ID: 23782585
[TBL] [Abstract][Full Text] [Related]
12. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
He YL; Sabo R; Picard F; Wang Y; Herron J; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2009 May; 25(5):1265-72. PubMed ID: 19364302
[TBL] [Abstract][Full Text] [Related]
13. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
Ahrén B; Foley JE; Bosi E
Diabetes Obes Metab; 2011 Mar; 13(3):193-203. PubMed ID: 21205107
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.
Wang X; Zhang D; Xu W; Liu H; Wang W
Xenobiotica; 2010 Oct; 40(10):707-12. PubMed ID: 20735236
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
He YL; Serra D; Wang Y; Campestrini J; Riviere GJ; Deacon CF; Holst JJ; Schwartz S; Nielsen JC; Ligueros-Saylan M
Clin Pharmacokinet; 2007; 46(7):577-88. PubMed ID: 17596103
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.
He YL; Paladini S; Sabia H; Campestrini J; Zhang Y; Leon S; Ligueros-Saylan M; Jarugula V
Int J Clin Pharmacol Ther; 2008 May; 46(5):259-67. PubMed ID: 18538112
[TBL] [Abstract][Full Text] [Related]
18. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
Ayalasomayajula SP; Dole K; He YL; Ligueros-Saylan M; Wang Y; Campestrini J; Humbert H; Sunkara G
Curr Med Res Opin; 2007 Dec; 23(12):2913-20. PubMed ID: 17931461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
